Company: IMRX
Filing Date: 2025-08-25
Form Type: 8-K
Source: 0001104659-25-081995
Chunk: 0

Company: Immuneering Corp
Filing Date: 2025-08-25
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into a Material Definitive Agreement.

On August 21, 2025, Immuneering Corporation (the
“ Company”) entered into a Securities Purchase Agreement (the “ Purchase Agreement”) with the purchasers party thereto (the “ Investors”), pursuant to which the Company agreed to sell securities to the Investors in a private
placement (the “ Private Placement”). The Purchase Agreement provided for the sale and issuance by the Company of: (i) an
aggregate of 6,329,113 shares (the “ Shares”) of the Company’s Class A common stock, par value $0.001 per share
(the “ Common Stock”) (or, for certain investors in lieu of Common Stock, pre-funded warrants to purchase shares of
Common Stock (the “ Pre-Funded Warrants”), with an exercise price of $0.001 per share), and (ii) accompanying
warrants to purchase up to 2,848,096 shares of Common Stock (the “ Purchase Warrants”), with an exercise price of $5.50
per share, for aggregate gross proceeds of approximately $25.0 million, before deducting private placement expenses. Each Share (or
Pre-Funded Warrant to purchase one share) was issued with an accompanying Purchase Warrant to purchase 45% of one share, and
the combined effective purchase price per Share (or Pre-Funded Warrant to purchase one share) and accompanying Purchase Warrant to
purchase 45% of one share was $3.95 (less the exercise price of the Pre-Funded Warrant, if applicable).

Each of the Investors is party to a confidentiality agreement with the Company, pursuant to which the Company has disclosed certain information
to such Investors. Pursuant to the terms of the Purchase Agreement, each Investor has agreed, severally and not jointly, that neither
it nor any affiliate acting on its behalf will execute any purchases or sales of any of the Company's securities during the period commencing
on August 21, 2025 and ending at such time that the Company files a Current Report on Form 8-K (on or prior to November 30, 2025) disclosing
such information previously disclosed to such Investor.

The closing of the Private Placement is expected to occur on or about August 26,
2025 (the “ Closing Date”).

The Pre-Funded Warrants are immediately exercisable until
exercised in full, subject to the Beneficial Ownership Limitation (as described below).